Eli Lilly (LLY) – The pharmaceutical giant ignites new growth surge with weight-loss medications and significantly raises annual forecast!
Reading Time: 3 minutes
Eli Lilly delivers a quarter to marvel at: Revenue +56% to $19.8 billion, EPS at $8.55 far exceeds expectations. Mounjaro and Zepbound drive the boom, with the annual forecast significantly raised. With the oral candidate Foundayo and a robust pipeline, LLY positions itself as a heavyweight in the billion-dollar GLP-1 market. Quarterly figures exceed expectations – Mounjaro and Zepbound drive revenue to record levels The stock of Eli Lilly rises sharply following strong quarterly figures, benefiting mainly from the ongoing boom surrounding...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
